We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 345.00 | 340.00 | 350.00 | 345.00 | 345.00 | 345.00 | 19,287 | 07:43:32 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 44.26M | -23.57M | -0.2277 | -18.88 | 445.07M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/7/2019 11:09 | dave - I don't think so. He's removed the full list of holdings from his site - doesn't like his trading being tracked I guess! - so it's impossible to be sure, but the last figures I can find are for December 2017, when there was no trace of Maxcyte. It seems unlikely he's bought anything much since then - he had more than enough small biotech as it was. pug - to get EIS (substantial) tax benefits you have to hold for 3 years, so unlikely to be them. It is thinly-traded, though, so any buy/sell is going to move the price, but another day like Friday and the company will have to say something. A pity this is so unloved - there's huge interest in CAR-T. I see a nearly two-hour documentary on BBC2 tonight on a trial for CAR-T in leukemia: Probably a lot more emotion than science, but probably still worth a watch. | supernumerary | |
06/7/2019 19:53 | More likely those who bought at IPO and now locking in profits (that is if I undersatnd the EIS scheme correctly - as expalined by TIMBO in the heading) or possibly MOS tip buyers having stop-loss points being triggered. Woodford lot listed on coy web-site as a significant holder. Also a Delaware registered company which is a Red Flag for some . | pugugly | |
06/7/2019 11:13 | Woodford selling, (not sure if he has a holding)? | davep4 | |
05/7/2019 18:29 | Mmmm... joint broker appointed in June - fund raising? Or just a holder getting out? | supernumerary | |
26/5/2019 10:06 | Midas - Mail on Sunday BUY tip so should be good for a bounce on Tuesday - Still usual high risk mini-pharma (imo) | pugugly | |
08/5/2019 15:46 | Hard to disagree with any of that, but the fact remains that over the last couple of years the share price has fallen steadily, and without dividends that and promises are all you've got. I think they might have to come a bit cleaner about the mid-term pipeline. I've got no idea whether their licensees are all in pre-clinical or whether some at least are closer to major milestones. Since that's a major part of the value proposition, in particular in potentially ending the need for continual cash raises, it needs more visibility to reassure investors. An indication of efficacy for MCY-M11 would also be useful! | supernumerary | |
08/5/2019 11:50 | How to find a bargain in the British market By: Richard Penny 19/04/2019 Each week, a professional investor tells us where he’d put his money. This week: Richard Penny of the FP CRUX UK Special Situations Fund chooses three top-quality stocks. Investment is often characterised as a trade-off between value and growth. However, this is not the case. Growth is a feature of a business, and value is a reflection of what you pay for shares in relation to their inherent qualities. It is possible for a low-growth company to be expensive, while growing companies can also be acquired cheaply. Investors are always on the hunt for a “bargain” When it comes to finding these, we consider key factors to be an ability to generate cash, management demonstrating alignment with shareholders’ interests by investing in the business, and the sustainability of growth and returns. Smaller businesses often display these characteristics, and because institutional investors tend to ignore them they can trade at big discounts to larger peers. Sometimes a business that would be highly valued as a standalone business is tucked away inside a large global entity. Bargains also arise when a company looking to grow depresses current profits by investing in new areas, prompting investors to mark it down, thus masking its true value. Analysing the reasons why a seemingly high-quality company has a downtrodden valuation is important. By tuning out market noise and taking a long-term view, you will greatly improve your odds of finding a bargain in the UK market. A leader in healthcare Among the smaller companies at the forefront of rapid developments in the healthcare sector is MaxCyte (Aim: MXCT), a world leader in the field of gene therapy. MaxCyte supplies machines critical to the modification of human genes to 20 of the world’s top 25 pharmaceutical companies and boasts a portfolio of around 70 licensing deals. The investment case includes MaxCyte’s commitment to undertaking clinical trials to combat ovarian cancer. This is a riskier part of the business, but it could pay dividends: other similar platforms are selling at multiples of MaxCyte’s current valuation. | davep4 | |
08/5/2019 09:35 | I'm struggling to understand what's happening here. I thought the results were good, this is a positive result, everything seems on track, but it remains unloved. Is it just worries about money, or is there a holder who's keen to reduce? Tim - was there any indication from the presentation of when they saw income from their '70 partnered programme licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering potentially more than 30 products with aggregate potential milestones of more than $250m plus significant additional potential milestones from the multi-drug commercial agreement with Kite announced 1 March 2019.' arriving? This must hold the key to their finances going forward. | supernumerary | |
02/5/2019 11:09 | tim - did you ever produce those notes? | supernumerary | |
25/4/2019 15:18 | I was at a Maxcyte investor briefing earlier today at Panmure Gordon and I will be seeing Doug again at the Proactive investor meeting this evening, will try to write up a few consolidated notes sometime tomorrow. | timbo003 | |
25/4/2019 10:07 | Morning. Short TV interview with Doug Doerfler following yesterday's results: www.fmp-tv.co.uk/com | oshy92 | |
01/4/2019 17:25 | Interesting results in hard to treat cancers emerging: | supernumerary | |
21/1/2019 16:15 | For sure there'll be companies looking. | supernumerary | |
21/1/2019 15:48 | probably a takeover target right? | edwardt | |
17/1/2019 20:47 | In the absence of decisive information, I'm waiting... | supernumerary | |
17/1/2019 17:24 | all very exciting but as they are about to run out of cash - shall i wait to post raise to get onboard? new here so happy to be shot down... | edwardt | |
21/12/2018 18:01 | This one could run and run... A new journal paper published late last week revealed that a “cutting&rdquo The paper, published on bioRxiv (but as yet to be peer-reviewed), saw researchers undertake blood tests on a few dozen people. “The presence of pre-existing adaptive immune responses in humans to either Cas9 homolog may hinder the safe and efficacious use of the Cas9/gRNA system to treat disease, and may even result in significant toxicity to patients,” the study found. This is because the most widely used homologs of the Cas9 protein are derived from the bacteria Staphylococcus aureus (S. aureus) and Streptococcus pyogenes (S. pyogenes). [...] | supernumerary | |
05/12/2018 09:28 | New Trinity Delta research note out this morning . . | timbo003 | |
14/11/2018 12:16 | New interview with Doug (from yesterday) | timbo003 | |
14/11/2018 08:27 | Maxcyte are getting a good bit of momemtum on new commercial licencing agreements I know very little about Precison Biosciences or their ARCUS technology, but I see they raised $110m last summer and they have some big backers behind them | timbo003 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions